Fierce Pharma
DECEMBER 7, 2023
When it comes to manufacturing cell therapies, it's often said that the "process is the product." But churning out these complex, individualized drugs has routinely tripped up even the industry's l | In recent months, Novartis has faced scrutiny from the FDA over Kymriah production shortfalls, a newly posted letter shows. The company says it's working to address the situation.
MedCity News
DECEMBER 7, 2023
Embracing the possibilities that AI unlocks, our commitment to seamlessly integrating AI into healthcare workflows reflects our belief that technology should melt into the background, empowering human caregivers to focus on delivering compassionate patient care.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Fierce Pharma
DECEMBER 7, 2023
In the currently mismatched CD38 antibody race, Sanofi’s Sarclisa has delivered a pivotal trial win, which might help the lagging follower level the playing field a little. | In the currently mismatched CD38 antibody race, Sanofi’s Sarclisa has delivered a pivotal trial win, which might help the lagging follower level the playing field a little with Johnson & Johnson.
MedCity News
DECEMBER 7, 2023
Researchers recently tested ChatGPT’s ability to answer patient questions about medication, finding that the AI model gave wrong or incomplete answers about 75% of the time. Providers should be wary of the fact that the model does not always give sound medical advice, given many of their patients could be turning to ChatGPT to answer health-related questions.
Fierce Pharma
DECEMBER 7, 2023
Merck has called it quits on another attempt to enhance its powerful PD-1 inhibitor Keytruda in non-small cell lung cancer (NSCLC). | Merck has called it quits on another attempt to enhance its powerful PD-1 inhibitor Keytruda in non-small cell lung cancer just as its TIGIT program goes up in flames.
MedCity News
DECEMBER 7, 2023
During a webinar, three health system leaders discussed strategies they use to ensure successful AI deployment. They agreed that one of the best ways health systems can prime themselves for fruitful AI deployments is beginning with a specific problem to solve — as opposed to having AI startups tell them which problems need to be addressed.
Pharma Rep Focus brings together the best content for pharma rep professionals from the widest variety of industry thought leaders.
MedCity News
DECEMBER 7, 2023
During a critical nursing shortage, practicing nurses want to be allowed more time for teaching and mentoring fellow nurse learners, as there are multiple benefits for both sides that could result in improved satisfaction.
Fierce Pharma
DECEMBER 7, 2023
WuXi Biologics' gloomy business update triggered a stock market avalanche. Daiichi Sankyo and Novartis reached a $182 million settlement on their BRAF drug patent dispute. | WuXi Biologics' gloomy business update triggered a stock market avalanche. Daiichi Sankyo and Novartis reached a $182 million settlement on their BRAF drug patent dispute.
European Pharmaceutical Review
DECEMBER 7, 2023
Results from a world-first human trial, published in the New England Journal of Medicine , has shown that a drug called baricitinib has promise as the first disease-modifying treatment of its kind for type 1 diabetes, that can be administered as a tablet. baricitinib… [demonstrated an ability to] preserve the body’s own insulin production and suppress the progression of type 1 diabetes in people who initiated treatment within 100 days of diagnosis” The researchers noted that baricit
Fierce Pharma
DECEMBER 7, 2023
The antifungal agent Amphotericin B is highly effective against a wide range of deadly fungi and resistance is rare, even after decades of use. | Amphotericin B, an effective antifungal with rare resistance, is associated with significant kidney damage, prompting the search for a potential alternative. This week on "The Top Line," Fierce Biotech Research’s Helen Floersh spoke with Martin Burke, M.D., Ph.D., founder of antifungal startup Sfunga Therapeutics, to discuss the design and pa
Advertisement
Clinical trial data management is increasingly challenging as studies grow in complexity. Quickly accessing and analyzing study data is vital for assessing trial progress and patient safety. In this paper, we explore real-time data access and analysis for proactive study management. We investigate using adverse event (AE) data to monitor safety and discuss a clinical analytics platform that supports collaboration and data review workflows.
pharmaphorum
DECEMBER 7, 2023
AbbVie has announced its second major takeover deal in the space of a few days, offering $8.7 billion to buy central nervous system drug specialist Cerevel Therapeutics which spun out of Pfizer in 2018.
Fierce Pharma
DECEMBER 7, 2023
Vanda Pharmaceuticals has a new commercial asset under its belt after striking a deal to buy certain rights to Johnson & Johnson’s multiple sclerosis med Ponvory for $100 million. | The multiple sclerosis drug has "potentially broad applications," Vanda's CEO said. J&J launched the med in 2021 and has yet to reveal its sales figures.
MedCity News
DECEMBER 7, 2023
By understanding the interconnectedness of the healthcare industry, aligning goals and maintaining an open line of communication, distributors and healthcare organizations can cultivate lasting, dependable partnerships, while working together to develop innovative ideas and solutions.
PharmExec
DECEMBER 7, 2023
Arthritis, asthma, cancer, cardiovascular diseases, chronic kidney disease, COPD, depression, and diabetes reach the highest recorded levels since the America’s Health Rankings Annual Report began tracking them in 1990.
Advertisement
Planning on running clinical trials in Japan? How can you reliably supply these studies? Discover Catalent’s clinical supply packaging facility in Shiga, Japan. Strategically located between Tokyo and Osaka, and one of largest in Japan, this 6,000 square meter facility offers comprehensive services including primary and secondary clinical packaging and labelling, comparator sourcing, cold chain storage, local and global distribution, local language support and white glove service to support stud
Pharmaceutical Technology
DECEMBER 7, 2023
Japan has granted approval for the sBLA of Bristol-Myers Squibb (BMS) for Abecma to treat relapsed or refractory multiple myeloma (RRMM).
pharmaphorum
DECEMBER 7, 2023
Treatment with Eli Lilly’s JAK inhibitor Olumiant has been shown to preserve the function of insulin-producing pancreatic beta cells in patients with type 1 diabetes, potentially opening up a whole new avenue of therapy.
European Pharmaceutical Review
DECEMBER 7, 2023
A report from the Advanced Therapies Treatment Centre (ATTC) Network has highlighted urgent need for rapid change and improvement in the field to maximise patient access to advanced therapies. It was compiled based on expertise gathered at the ATTC Network’s UK Advanced Therapies Adoption Challenge event in October. At the event, attendees discussed barriers and develop solutions to the advanced therapies adoption challenge.
Pharmaceutical Technology
DECEMBER 7, 2023
The FDA has granted fast track designation to Solid Biosciences’s gene therapy SGT-003 for the treatment of DMD.
Advertisement
Clinical research has entered a new era, one that requires real-time analytics and visualization to allow trial leaders to work collaboratively and to develop, at the click of a mouse, deep insights that enable proactive study management. Learn how Revvity Signals helps drug developers deliver clinical trial data insights in real-time using a fast and flexible data and analytics platform to empower data-driven decision-making.
pharmaphorum
DECEMBER 7, 2023
Medtech giant Medtronic has decided not to go ahead with a planned acquisition of EOFlow, a developer of patch-based insulin pumps, saying that there have been “multiple breaches” of their takeover agreement.
MedCity News
DECEMBER 7, 2023
MedKitDoc Founder Dorian Koch shared the journey of the startup, which wants to transform the way patients receive healthcare.
PharmaTimes
DECEMBER 7, 2023
The disease is one of the leading causes of cancer deaths in the UK - News - PharmaTimes
pharmaphorum
DECEMBER 7, 2023
Sanofi said this morning that its pipeline includes 12 potential blockbuster drugs that could generate more than €10 billion ($11 billion) in annual sales by the end of the decade, a sharp increase on earlier predictions.
Advertisement
When selecting a clinical supply provider, consideration often focuses upon the manufacturing, packaging, storage and distribution capabilities available that will, at face-value, be sufficient to meet the needs of the sponsor and their trial. However, there are human-based and knowledge-driven factors that are often overlooked that go beyond these basic physical capabilities and are integral to the development and delivery of high performing clinical supply chains.
Clarivate
DECEMBER 7, 2023
Research and development (R&D) plays a fundamental role in generating the innovation that is essential for maintaining competitive advantage. We are pleased that Clarivate is included in the recently released Gartner report, Market Guide for Intellectual Property Management Software With R&D-specific Use Cases. “This guide offers R&D leaders a sampling of available IP management products that deliver on R&D-related use cases.
pharmaphorum
DECEMBER 7, 2023
The FDA has kicked off a priority review of Genfit and Ipsen’s elafibranor as a treatment for rare cholestatic liver disease primary biliary cholangitis (PBC), setting a date of 10th June to deliver a decision.
PharmaVoice
DECEMBER 7, 2023
Shankar Narayanan, CEO of marketing consulting firm Real Chemistry, weighs in on where the industry is headed in the New Year.
Rep-Lite
DECEMBER 7, 2023
Getting into pharmaceutical sales and selling pharmaceutical products may require patience and persistence, but for individuals with the right qualifications and a passion for the field, it can be a rewarding and financially lucrative career. In this article, we’ll delve into the intricacies of how to get into pharmaceutical sales and the pivotal role of training.
Advertisement
Clinical development organizations face a wide array of challenges when it comes to data, many of which can impact the operational effectiveness of their clinical trials. In this whitepaper, experts from Revvity Signals explore how solutions like TIBCO® Spotfire® enable better, more streamlined studies. The whitepaper also features a success story from Ambrx, a leading biopharmaceutical company, detailing how it has leveraged Spotfire to tackle data quality and collaboration challenges in clinic
Contrarian Sales Techniques
DECEMBER 7, 2023
Ever wondered why some Amazon sellers seem to have the Midas touch? Today, we're diving into the secrets that can turn your listings into gold. Whether you're just starting out or looking to up your game, these insider tips are your ticket to skyrocketing sales on Amazon. So, grab a coffee, and let's unravel the mysteries of Amazon success together. 1.
Pharmaceutical Technology
DECEMBER 7, 2023
GlobalData’s report assesses the drugs in the Calcitonin Gene Related Peptide Type 1 Receptor pipeline by therapy areas, indications, stages, MoA, RoA, molecule type and the key players in the development pipeline.
Contrarian Sales Techniques
DECEMBER 7, 2023
Wondering about, "What is sales in banking?" Well, you're not alone. As someone who's navigated the banking world from a customer's viewpoint, I've got some insights to share. Imagine we're just a couple of friends talking over coffee, and I'm about to unravel the mystery of sales in the banking sector. What is Sales in Banking? Sales in banking, simply put, is the process where banks and financial institutions persuade us, the customers, to use their products and services.
Pharmaceutical Technology
DECEMBER 7, 2023
GlobalData’s report assesses the drugs in the Calcitonin Gene Related Peptide Type 1 Receptor pipeline by therapy areas, indications, stages, MoA, RoA, molecule type and the key players in the development pipeline.
Advertisement
As the development pipeline for new drugs continues to grow, biopharmaceutical companies are re-evaluating how to best manage and balance resources across an increasing number of development projects and complex clinical trials. There are two approaches that can be used to speed a drug from development to clinic faster: timeline compression and parallel processing, but only one that considers the benefits of integrating clinical supply into the overall drug development process.
Expert insights. Personalized for you.
280 
Let's personalize your content